Springe zum Inhalt
| Eingeschlossene Patienten: 18.537 (Stand 01. Juli 2019) | |
| Amgevita® (Adalimumab) | 25 |
| Benepali® (Etanercept) | 583 |
| Cimzia® (Certolizumab) | 880 |
| Enbrel® (Etanercept) | 2856 |
| Erelzi® (Etanercept) | 164 |
| Flixabi® (Infliximab) | 2 |
| Hulio® (Adalimumab) | 1 |
| Humira® (Adalimumab) | 2902 |
| Hyrimoz® (Adalimumab) | 29 |
| Imraldi® (Adalimumab) | 25 |
| Inflectra™ (Infliximab) | 16 |
| Kevzara® (Sarilumab) | 77 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1461 |
| Olumiant® (Baricitinib) | 276 |
| Orencia® (Abatacept) | 763 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 10 |
| Rixathon® (Rituximab) | 7 |
| RoActemra® (Tocilizumab) | 1311 |
| Simponi® (Golimumab) | 439 |
| Xeljanz® (Tofacitinib) | 220 |
| Zessly® (Infliximab) | 1 |
| Kontrollen | 5638 |
Nach oben scrollen
